Table 2.
High-Risk Model: Maternal and Infant Characteristics Associated with Neonatal Abstinence Syndrome Among Infants Exposed to Opioids or Hepatitis C.
| No Diagnosis of Neonatal Abstinence Syndrome |
Neonatal Abstinence Syndrome | p-value | |
|---|---|---|---|
| N=14884 | N=1446 | ||
| Infant Characteristics | |||
| Birthweight (g), Median (IQR) | 3119 (2770-3430) | 3005 (2665-3306) | <0.001 |
| Gestational Age (weeks), Median (IQR) | 39 (38-39) | 39 (38-40) | 0.13 |
| Small for Gestational Age, % (N) | 22 (3214) | 32 (457) | <0.001 |
| Female, % (N) | 49 (7306) | 44 (637) | <0.001 |
| Maternal Characteristics | |||
| Maternal Age, Median (IQR) | 25 (21-28) | 26 (23-30) | <0.001 |
| Hepatitis C Virus Positive, % (N) | 2 (295) | 16 (237) | <0.001 |
| Medication Exposures in Last 30 Days of Pregnancy | |||
| Immediate-Release Opioid (days), Median (IQR) | 4 (2-10) | 0 (0-3) | <0.001 |
| Sustained-Release Opioid (days), Median (IQR) | 0 (0-0) | 0 (0-0) | <0.001 |
| MOUD (days), Median (IQR) | 0 (0-0) | 22 (0-30) | <0.001 |
| Benzodiazepine, % (N) | 1 (125) | 4 (55) | <0.001 |
| Antipsychotics, % (N) | 1 (122) | 2 (26) | <0.001 |
| SSRI, % (N) | 5 (705) | 8 (120) | <0.001 |
| Zolpidem, % (N) | 5 (764) | 3 (41) | <0.001 |
| Bupropion, % (N) | 1 (136) | 2 (24) | 0.006 |
| Reflux and Anti-Nausea, % (N) | 26 (3920) | 22 (324) | 0.001 |
| Number of Cigarettes per Day, Median (IQR) | 0 (0-8) | 10 (0-13) | <0.001 |